此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study

2015年11月10日 更新者:Xianglin Yuan、Huazhong University of Science and Technology
This prospective cohort study aims to observe the efficacy and safety of the first-line combined chemotherapy for advanced gastric cancer(AGC) in Chinese population.

研究概览

地位

未知

条件

详细说明

  1. Establish a clinical database for the advanced gastric cancer patients treated with first-line combined chemotherapy in Tongji hospital.

    1.1.Data including age, gender, smoking state, karnofsky performance score(KPS), disease history, clinical stage, primary tumor site, metastasis site, surgery, first-line chemotherapy, therapy after failure of first-line treatment, radiotherapy, toxicity, survival time, the time of free of progress, response were collected.

    1.2.The peripheral blood samples were collected for further biomarker reserch.

  2. Kaplan-Meier and Cox model will be used to analyze the overall survival(OS) and progression-free survival(PFS) of advanced gastric cancer.
  3. Extract Deoxyribonucleic acid(DNA) from the the peripheral blood and research biomarkers related to the first-line combined chemotherapy for AGC.

研究类型

观察性的

注册 (预期的)

250

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Hubei
      • Wuhan、Hubei、中国、430030
        • 招聘中
        • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
        • 首席研究员:
          • Xianglin Yuan, MD,PHD
        • 接触:
        • 接触:
        • 副研究员:
          • Suxian Wei, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

Histopathology or cytopathology confirmed unresectable locally advanced, or recurrent, or metastatic chemotheapy-naive gastric cancer and gastroesophageal adenocarcinoma patients

描述

Inclusion Criteria:

  1. Histopathology or cytopathology proven gastric cancer or gastroesophageal adenocarcinoma;
  2. Unresectable locally advanced, or recurrent, or metastasis disease;
  3. Chemotherapy-naive or disease progress at least 6 months after adjuvant chemotherapy completed.
  4. Life expectancy of at least 3 months;
  5. ECOG score 0-2;
  6. Voluntarily signed the informed consent.

Exclusion criteria:

  1. Previously treated with first-line chemotherapy;
  2. First-line chemotherapy with single drug.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Combined chemotherapy
AGC patients treated with first-line combined chemotherapy

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Overall survival(OS) . overall survival Overall survival(OS)
大体时间:From date of enrollment until the date of death from any cause, assessed up to 60 months
From date of enrollment until the date of death from any cause, assessed up to 60 months

次要结果测量

结果测量
大体时间
Progression-free survival(PFS)
大体时间:From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Objective response rate(ORR)
大体时间:The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
Disease control rate(DCR)
大体时间:The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
大体时间:Through first-line treatment completion,up to 24 weeks.
Through first-line treatment completion,up to 24 weeks.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Xianglin Yuan, MD,PHD、Tongji Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2013年1月1日

初级完成 (预期的)

2016年6月1日

研究完成 (预期的)

2018年1月1日

研究注册日期

首次提交

2015年10月19日

首先提交符合 QC 标准的

2015年10月20日

首次发布 (估计)

2015年10月22日

研究记录更新

最后更新发布 (估计)

2015年11月11日

上次提交的符合 QC 标准的更新

2015年11月10日

最后验证

2015年10月1日

更多信息

与本研究相关的术语

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅